These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 27232238)

  • 1. Some Numbers behind Canada's Decision to Adopt an Orphan Drug Policy: US Orphan Drug Approvals in Canada, 1997-2012.
    Herder M; Krahn TM
    Healthc Policy; 2016 May; 11(4):70-81. PubMed ID: 27232238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998.
    Rawson NS
    CMAJ; 2000 Feb; 162(4):501-4. PubMed ID: 10701383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating the landscape of US orphan product approvals.
    Miller KL; Lanthier M
    Orphanet J Rare Dis; 2018 Oct; 13(1):183. PubMed ID: 30348193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The drug lag and associated factors for orphan anticancer drugs in Japan compared to the United States.
    Nakayama H; Matsumaru N; Tsukamoto K
    Invest New Drugs; 2019 Oct; 37(5):1086-1093. PubMed ID: 29855823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
    Richey EA; Lyons EA; Nebeker JR; Shankaran V; McKoy JM; Luu TH; Nonzee N; Trifilio S; Sartor O; Benson AB; Carson KR; Edwards BJ; Gilchrist-Scott D; Kuzel TM; Raisch DW; Tallman MS; West DP; Hirschfeld S; Grillo-Lopez AJ; Bennett CL
    J Clin Oncol; 2009 Sep; 27(26):4398-405. PubMed ID: 19636013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of the Orphan Drug Act on Food and Drug Administration-approved therapies for rare skin diseases and skin-related cancers.
    Karas L; Lu CY; Agrawal PB; Asgari MM
    J Am Acad Dermatol; 2019 Sep; 81(3):867-877. PubMed ID: 31103566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of numbers and timing of new medication regulatory approvals in Canada and New Zealand.
    Rawson NSB
    Regul Toxicol Pharmacol; 2019 Feb; 101():24-28. PubMed ID: 30391284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapies for inborn errors of metabolism: what has the orphan drug act delivered?
    Talele SS; Xu K; Pariser AR; Braun MM; Farag-El-Massah S; Phillips MI; Thompson BH; Coté TR
    Pediatrics; 2010 Jul; 126(1):101-6. PubMed ID: 20566615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fair pricing of "old" orphan drugs: considerations for Canada's orphan drug policy.
    Roberts EA; Herder M; Hollis A
    CMAJ; 2015 Apr; 187(6):422-425. PubMed ID: 25712953
    [No Abstract]   [Full Text] [Related]  

  • 10. A cross-national comparison of orphan drug policies: implications for the U.S. Orphan Drug Act.
    Thamer M; Brennan N; Semansky R
    J Health Polit Policy Law; 1998 Apr; 23(2):265-90. PubMed ID: 9565894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The study of drugs for rare disorders: harnessing research contributions by Canadian academic institutions.
    Macleod S; Lasko P; Mackenzie A
    J Popul Ther Clin Pharmacol; 2014; 21(1):e47-55. PubMed ID: 24671865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
    Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulators adopt more orphan drugs.
    Reardon S
    Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293
    [No Abstract]   [Full Text] [Related]  

  • 14. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years.
    Braun MM; Farag-El-Massah S; Xu K; Coté TR
    Nat Rev Drug Discov; 2010 Jul; 9(7):519-22. PubMed ID: 20531273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health Canada's use of expedited review pathways and therapeutic innovation, 1995-2016: cross-sectional analysis.
    Lexchin J
    BMJ Open; 2018 Aug; 8(8):e023605. PubMed ID: 30166310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric Orphan Drug Indications: 2010-2018.
    Kimmel L; Conti RM; Volerman A; Chua KP
    Pediatrics; 2020 Apr; 145(4):. PubMed ID: 32127360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Precision Medicines' Impact on Orphan Drug Designation.
    Mueller CM; Rao GR; Miller Needleman KI
    Clin Transl Sci; 2019 Nov; 12(6):633-640. PubMed ID: 31297924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health Canada's Use of its Notice of Compliance With Conditions Drug Approval Policy: A Retrospective Cohort Analysis.
    Lexchin J
    Int J Health Serv; 2019 Apr; 49(2):294-305. PubMed ID: 30587064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis.
    Thorat C; Xu K; Freeman SN; Bonnel RA; Joseph F; Phillips MI; Imoisili MA
    Pediatrics; 2012 Mar; 129(3):516-21. PubMed ID: 22371464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel treatments for rare rheumatologic disorders: analysis of the impact of 30 years of the US orphan drug act.
    Lutz T; Lampert A; Hoffmann GF; Ries M
    Orphanet J Rare Dis; 2016 May; 11(1):60. PubMed ID: 27176041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.